A5053474234- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Microplastics and Plastic Pollution
- Cancer survivorship and care
- Recycling and Waste Management Techniques
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Service and Product Innovation
- Male Breast Health Studies
- Influenza Virus Research Studies
- HER2/EGFR in Cancer Research
- Cervical Cancer and HPV Research
- Inflammatory Biomarkers in Disease Prognosis
- Infections and bacterial resistance
- Cancer Cells and Metastasis
- Medication Adherence and Compliance
- Neuroendocrine Tumor Research Advances
- Pharmaceutical Practices and Patient Outcomes
- Infectious Diseases and Mycology
Luigi Sacco Hospital
2024-2025
ASST Fatebenefratelli Sacco
2022-2024
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2020-2024
University of Milan
2020-2024
People with HIV and cancer (PWHC) are often treated different combinations of antiretroviral oncology drugs, frequently associated other co-medications; this significantly increases the risk potential drug-drug interactions (DDIs). A prospective observational study has been carried out from May 2020 to 2024 describe management therapies in PWHC an outpatient clinic. 140 42 59 regimens were enrolled, resulting identification 410 DDIs. Of these, 8% scored as red-flag DDIs). Among medications,...
oxaliplatin with fluoropyrimidine is a "mainstay" regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, efficacy and safety oxaliplatin-based regimens in late-care settings have been poorly reported.we identified real-world mCRC patient cohort who were re-treated oxaliplatin, which clinicopathological features retrospectively analyzed to identify efficacy-predictive determinants (RETROX-CRC study).of 2606 patients, 119 fulfilled eligibility criteria....
Abstract Introduction Cancer patients are frail individuals, thus the prevention of SARS‐CoV‐2 infection is essential. To date, vaccination most effective tool to prevent COVID‐19. In a previous study, we evaluated immunogenicity two doses mRNA‐based vaccines (BNT162b2 or mRNA‐1273) in solid cancer patients. We found that seroconversion rate without exposure was lower than healthy controls (66.7% vs. 95%, p = 0.0020). The present study aimed evaluate clinical efficacy same population....
•Largest dataset of NSCLC with uncommon EGFR alterations treated osimertinib.•Best outcomes compound uncommon–common mutations and G719X, L861X, or S768I.•Heterogeneous activity rarer mutations; no response at E709 residue.•Confirmed in the central nervous system, intracranial ORR 58%.•Amplification MET, TP53 mutations, E709K are putative mechanisms resistance. BackgroundOsimertinib represents standard care for treatment advanced non-small-cell lung cancer (NSCLC) harboring classical...
Ralstonia spp. are low-virulent environmental Gram-negative bacteria that can cause serious nosocomial infections in immunocompromised patients. We report the characteristics of a cluster R. insidiosa bacteremia cases occurring our oncology day ward Milan, Italy, between January and March 2022. A case was defined as cancer patient attending whose blood culture (performed because symptoms) led to isolation insidiosa. An epidemiological investigation conducted order seek possible source...
In patients with cancer, tumor- and treatment-induced immunosuppression are responsible for a four-fold increase in morbidity mortality caused by influenza invasive Streptococcus pneumoniae infections compared to the general population. The main oncology societies strongly recommend vaccination cancer prevent these infections. However, vaccine hesitancy is concern this aim of study was assess feasibility in-hospital under anticancer treatment their family members (FMs) against pneumococcal...
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim our study is to evaluate two doses solid patients with or without previous exposure virus. This single-institution, prospective, nonrandomized study. Patients active treatment and control cohort healthy people received BNT162b2 (Comirnaty, BioNTech/Pfizer, United States) mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy first...
Abstract Solid cancer patients are at higher risk of SARS‐CoV‐2 infection and severe complications. Moreover, vaccine‐induced antibody response is impaired in on anticancer treatment. In this retrospective, observational, hypothesis‐generating, cohort study, we assessed the to third dose mRNA vaccine a convenience sample treatment, comparing it that primary two‐dose cycle. Among 99 included, 62.6% were ≥60 years old, 32.3% males, 67.7% with advanced disease. Exactly 40.4% receiving...
e22545 Background: 38% of cancer patients (pts) receive diagnosis major depressive disorder. According with the clinimetric approach staging psychiatric disease, 5-step model unipolar depression allows for evaluation extent disorder, its severity, and characteristics at a specific time in course disease. This study was aimed: a) to assess mental health quality life limited (LS) advanced/metastatic (AS) solid through join disorders; b) explore potential role severity oncological disease...
In the last years, awareness has grown regarding micro-nanoplastics (MNPs) effects on human health. Despite a large body of evidence about origin and distribution MNPs in environment, knowledge their impact health remains limited. this context, there is significant need to address potential carcinogenic risk MNPs, both intrinsic mediated by ability transport chemicals. Currently, carcinogenicity scarce heterogeneous, but reported increase incidence malignant tumors among younger populations,...
127 Background: Oxaliplatin in association with fluoropyrimidines is universally considered one of the most effective drugs for colorectal cancer and mainstay front-line treatment metastatic patients. In contrast efficacy safety profile oxaliplatin based regimens late-care space have been poorly conflictingly reported. Methods: We identified a real-world cohort (mCRC) patients undergoing repeated treatments single institution retrospectively analysed their clinicopathological features to...